GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Spexis AG (XSWX:SPEX) » Definitions » Institutional Ownership

Spexis AG (XSWX:SPEX) Institutional Ownership : 0.95% (As of Jun. 09, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Spexis AG Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Spexis AG's institutional ownership is 0.95%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Spexis AG's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Spexis AG's Float Percentage Of Total Shares Outstanding is 0.00%.


Spexis AG Institutional Ownership Historical Data

The historical data trend for Spexis AG's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Spexis AG Institutional Ownership Chart

Spexis AG Historical Data

The historical data trend for Spexis AG can be seen below:

2023-07-31 2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31 2024-05-31
Institutional Ownership 1.06 1.06 1.06 1.13 1.13 0.91 1.09 1.10 1.10 0.95

Spexis AG Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Spexis AG (XSWX:SPEX) Business Description

Traded in Other Exchanges
Address
Hegenheimermattweg 125, Allschwil, CHE, CH-4123
Spexis AG is a clinical-stage biopharmaceutical company. The company is engaged in the discovery and development of antibiotics and other specialty pharma products for severe or life-threatening diseases. The company's lead product, murepavadin, is in Phase III development against Pseudomonas aeruginosa - recognized as a critical priority 1 pathogen by World Health Organization. It has one operating segment focusing on the research and development and prospective commercialization of respiratory therapeutics addressing high unmet medical needs.

Spexis AG (XSWX:SPEX) Headlines

No Headlines